As of Feb 14, 2019 HUMANIGEN INC (OTCMKTS:HGEN) Sellers Declined Their Shorts By 2.52%

Change of 2.52% for HUMANIGEN INC (OTCMKTS:HGEN)’s shorted shares was registered. It was announced in February by FINRA the 15,500 shorted shares on HGEN. That’s 2.52% down from 15,900 shares. HUMANIGEN INC (OTCMKTS:HGEN) has 3,900 shares average volume. It’ll cost 4 days for HGEN to restore its former position.

Ticker’s shares touched $0.918 during the last trading session after 2.00% change.Humanigen, Inc. has volume of shares. Since February 14, 2018 HGEN has 0.00% and is . The stock the S&P500 by 0.00%.

Humanigen, Inc., a biopharmaceutical company, focuses on developing medicines for patients with neglected and rare diseases with focus on pediatric conditions in the United States.The company has $100.96 million market cap. The companyÂ’s lead product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal, and neurological problems.Currently it has negative earnings. It is also developing proprietary monoclonal antibodies, including lenzilumab, which is in Phase 1/2 clinical trial in patients with chronic myelomonocytic leukemia, and potentially for the treatment of juvenile myelomonocytic leukemia; and ifabotuzumab that has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies.

For more Humanigen, Inc. (OTCMKTS:HGEN) news announced briefly go to:,,, or The titles are as follows: “KaloBios Pharma craters after KB001-A results disappoint – Seeking Alpha” announced on January 06, 2015, “KaloBios Upgrades Stock to OTCQB Market Other OTC:HGEN – GlobeNewswire” on June 26, 2017, “KaloBios Pharmaceuticals: Undervalued Company With Huge Potential Catalyst – Seeking Alpha” with a publish date: December 27, 2013, “Humanigen completes enrollment in early-stage study of lenzilumab in myelomonocytic leukemia – Seeking Alpha” and the last “Comeback For KaloBios? – Seeking Alpha” with publication date: March 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.